CISSPECT is the radioactive look-a-like of cisplatin, worldwide one of the most used anticancer drugs. CISSPECT is currently being developed in collaboration with the Netherlands Cancer Institute and Amsterdam UMC, loc. VUmc in the Netherlands. The collaboration is focusing on lung cancer patients and head and neck cancer patients.
CISSPECT is a promising imaging agent for predicting the effectivity of cisplatin treatment and to prevent severe kidney toxicity. With CISSPECT, we can measure the uptake in the tumour and select patients for cisplatin chemotherapy. Also, it is possible to assess the concentration of cisplatin in the kidneys.
CISSPECT can improve cisplatin treatment and save patients from side effects such as kidney failure, loss of hearing, nausea and tiredness.
Karlijn van der Schilden
R&D Manager Medical Isotopes
To increase effectivity of cisplatin chemotherapy and improve quality of life for patients!
Most of the patients treated with cisplatin do not respond to the therapy.
In case of lung cancer patients, less than 8% benefit from this chemotherapy treatment. Many patients suffer from side effects. Therefore, it is very unfortunate that non-responders cannot be identified before treatment starts.
Also, 50% of patients treated with cisplatin for head and neck cancer in the Netherlands, do not know the outcome before the treatment starts.
With 195mPt CISSPECT we may possibly help physicians to select the right treatment for these two patient groups.
Dr. ELSE AALBERSBERG, Technical Physician,
Antoni van Leeuwenhoek ziekenhuis
When Pt-195m cisplatin shows good results in the planned first in human trial, next steps could possibly follow soon directly afterwards.
Then, when time is due, expectation is to provide physicians with an instrument to increase the cisplatin chemo therapy efficacy combined with external radio-beam treatment.
In addition, physicians will be able to safeguard their patients’ quality of life.
“If successful, Pt-195m cisplatin contributes to optimising treatment outcome of chemo(radio)therapy and reducing toxicity in a personalised approach.“